Expert Review of Precision Medicine and Drug Development
Overview
Expert Review of Precision Medicine and Drug Development is a scientific journal, published since 2016 in English. The journal's country of origin is United Kingdom.
Details
Details
Abbr.
Expert Rev Precis Med Drug Dev
Start
2016
End
Continuing
Frequency
Bimonthly
e-ISSN
2380-8993
Country
United Kingdom
Language
English
Metrics
Metrics
h-index / Ranks: 13168
16
SJR / Ranks: 12541
257
CiteScore / Ranks: 8566
3.00
Recent Articles
1.
Huma C, Hawon L, Sarisha J, Erdal T, Kevin C, Valentina K
Expert Rev Precis Med Drug Dev
. 2024 Mar;
9(1):3-16.
PMID: 38550554
Introduction: Patient selection remains challenging as the clinical use of re-irradiation (re-RT) increases. Re-RT data is limited to retrospective studies and small prospective single-institution reports, resulting in small, heterogenous data...
2.
Jagasia S, Tasci E, Zhuge Y, Camphausen K, Krauze A
Expert Rev Precis Med Drug Dev
. 2023 Nov;
8(1):33-42.
PMID: 37982134
Introduction: Radiation therapy (RT) is commonly used to treat cancer in conjunction with chemotherapy, immunotherapy, and targeted therapies. Despite the effectiveness of RT, tumor recurrence due to treatment resistance still...
3.
Leopold J
Expert Rev Precis Med Drug Dev
. 2023 Feb;
7(1):4-16.
PMID: 36778892
Introduction: Cardiovascular disease persists as the leading cause of death worldwide despite continued advances in diagnostics and therapeutics. Our current approach to patients with cardiovascular disease is rooted in reductionism,...
4.
Zhao J, Galvez C, Beckermann K, Johnson D, Sosman J
Expert Rev Precis Med Drug Dev
. 2021 Sep;
6(4):281-294.
PMID: 34485698
Introduction: NRAS was the first mutated oncogene identified in melanoma and is currently the second most common driver mutation in this malignancy. For patients with NRAS advanced stage melanoma refractory...
5.
Sweeney T, Quispe R, Das T, Juraschek S, Martin S, Michos E
Expert Rev Precis Med Drug Dev
. 2021 Aug;
6(4):247-258.
PMID: 34423130
Introduction: A biomarker is a substance, structure, or process that indicates the presence of a disease, infection, or environmental exposure. Clinically useful biomarkers are measurable, improve diagnostic or prognostic performance,...
6.
Ho M, Bianchi G, Anderson K
Expert Rev Precis Med Drug Dev
. 2021 Aug;
5(2):67-85.
PMID: 34414281
Introduction: Remarkable progress in molecular characterization methods has led to significant improvements in how we manage multiple myeloma (MM). The introduction of novel therapies has led to significant improvements in...
7.
Nieto S, Grodin E, Ray L
Expert Rev Precis Med Drug Dev
. 2021 Jul;
5(1):43-54.
PMID: 34291172
Introduction: The heritability of alcohol use disorder (AUD) is estimated to be ~50%; however, the genetic basis of the disease is still poorly understood. The genetic variants identified thus far...
8.
Sparks J
Expert Rev Precis Med Drug Dev
. 2021 Jun;
6(3):147-149.
PMID: 34124370
No abstract available.
9.
Lisby A, Flickinger Jr J, Bashir B, Weindorfer M, Shelukar S, Crutcher M, et al.
Expert Rev Precis Med Drug Dev
. 2021 May;
6(2):117-129.
PMID: 34027103
Introduction: Colorectal cancer (CRC) is one of the most-deadly malignancies worldwide. Current therapeutic regimens for CRC patients are relatively generic, based primarily on disease type and stage, with little variation....
10.
Hormuth 2nd D, Jarrett A, Lorenzo G, Lima E, Wu C, Chung C, et al.
Expert Rev Precis Med Drug Dev
. 2021 May;
6(2):79-81.
PMID: 34027102
No abstract available.